Cryptococcal meningitis Infections and Infestations Meningitis
Conditions
Interventions
Treatment Group 1:
Induction Treatment: Amphotericin 1 mg/kg/day for 4 weeks
Consolidation Treatment: Fluconazole 400 mg/day for 6 weeks
Secondary Prophylaxis: Fluconazole 200 mg/day
Treatment Gro
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients aged 15 years and older 2. HIV positive 3. Cryptococcal meningitis defined by a clinical syndrome consistent with cryptococcal meningitis and one or more of: positive Cerebrospinal Fluid (CSF) culture, positive cryptococcal antigen in CSF, positive CSF india ink test
Exclusion criteria
Exclusion criteria: 1. Pregnancy 2. Renal or liver failure 3. Active TB 4. Aged less than 15 years old
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality at 2 and 10 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Amended as of 19/03/2009: 1. Rates of disability at 10 weeks 2. Rates of clearance of yeasts from CSF at 6 months 3. Changes in immune parameters at 6 months 4. Combined death and disability at 6 months 5. Death at 6 months Initial information at the time of registration: 1. Duration of ventilation 2. Duration of supplemental oxygen 3. Duration of hospitalisation 4. Viral load in clinical specimens 5. Cytokine levels 6. Adverse effects | — |
Countries
Viet Nam
Outcome results
None listed